Pfizer Gets Bigger -- Is It Still Committed to Getting Smaller?

With Pfizer and Allergan both masters of the M&A game, there is good reason to believe that management will oversee an effective integration, following the announcement of a $160 billion deal. The notion that Pfizer could subsequently split into two businesses – an innovative pharmaceutical company and one focused on older, established products – appears increasingly distant, however.